Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis.

Fremanezumab is a new treatment for preventing episodic migraines. This research reviewed its effectiveness and safety through a systematic analysis. The study included four clinical trials with 1,764 participants. Researchers looked at how well fremanezumab worked compared to a placebo. They measured the percentage of patients experiencing at least a 50% reduction in migraines. They also tracked the number of migraine days each month. The results showed that fremanezumab significantly improved the responder rate. It also decreased the number of monthly migraine days. Specifically, the responder rate increased by 81%, and monthly migraine days decreased by nearly two days. These findings suggest that fremanezumab could be a valuable option for patients suffering from episodic migraines. Overall, this research contributes important data to support the use of fremanezumab for migraine prevention. Clinical relevance: This study confirms that fremanezumab is effective for reducing episodic migraine frequency and severity, offering patients a promising prevention option.